Showing results (11-20 of 29) with videos related to
Sort By:
Pageof 3
European Journal of Cancer (Oxford, England : 1990)|August 22, 2022
Trajectories of body weight change and survival among patients with mCRC treated with systemic therapy: Pooled analysis from the ARCAD databaseJan Franko, Jun Yin, Richard A Adams, et al.Journal of Medical Genetics|March 12, 2017
Comprehensive pharmacogenetic profiling of the epidermal growth factor receptor pathway for biomarkers of response to, and toxicity from, cetuximabAyman Madi, David Fisher, Timothy S Maughan, et al.European Journal of Cancer (Oxford, England : 1990)|January 16, 2022
Efficacy of anti-epidermal growth factor receptor agents in patients with RAS wild-type metastatic colorectal cancer ≥ 70 yearsDemetris Papamichael, Guilherme S Lopes, Curt L Olswold, et al.The Lancet. Oncology|June 7, 2011
Intermittent versus continuous oxaliplatin and fluoropyrimidine combination chemotherapy for first-line treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trialRichard A Adams, Angela M Meade, Matthew T Seymour, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 13, 2020
International Rare Cancers Initiative Multicenter Randomized Phase II Trial of Cisplatin and Fluorouracil Versus Carboplatin and Paclitaxel in Advanced Anal Cancer: InterAActSheela Rao, Francesco Sclafani, Cathy Eng, et al.Radiation Oncology (London, England)|August 27, 2021
Durvalumab (MEDI 4736) in combination with extended neoadjuvant regimens in rectal cancer: a study protocol of a randomised phase II trial (PRIME-RT)Catherine R Hanna, Sean M O'Cathail, Janet S Graham, et al.The Lancet. Oncology|October 17, 2016
Prognosis of patients with peritoneal metastatic colorectal cancer given systemic therapy: an analysis of individual patient data from prospective randomised trials from the Analysis and Research in Cancers of the Digestive System (ARCAD) databaseJan Franko, Qian Shi, Jeffrey P Meyers, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 13, 2021
Capecitabine Versus Active Monitoring in Stable or Responding Metastatic Colorectal Cancer After 16 Weeks of First-Line Therapy: Results of the Randomized FOCUS4-N TrialRichard A Adams, David J Fisher, Janet Graham, et al.Lancet (London, England)|June 7, 2011
Addition of cetuximab to oxaliplatin-based first-line combination chemotherapy for treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trialTimothy S Maughan, Richard A Adams, Christopher G Smith, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 20, 2021
Inhibition of WEE1 Is Effective in TP53- and RAS-Mutant Metastatic Colorectal Cancer: A Randomized Trial (FOCUS4-C) Comparing Adavosertib (AZD1775) With Active MonitoringJenny F Seligmann, David J Fisher, Louise C Brown, et al.Pageof 3